North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.510

-3.8%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don W Stone who wrote ()	1/24/2000 11:38:00 AM
From: Paul Lee	of 507

North American Vaccine Files for UK Regulatory Approval of NeisVac-C(TM) COLUMBIA, Md., Jan. 24 /PRNewswire/ -- North American Vaccine (Amex: NVX) confirmed today that it has filed for regulatory approval of the Company's group C meningococcal conjugate vaccine, NeisVac-C(TM), in the United Kingdom. Submitting the filing for UK regulatory approval is one of the steps necessary for the Company to satisfy a commitment from the UK National Heath Service to purchase 3 million doses of this vaccine in 2000 for approximately $65 million, subject to UK regulatory approval. Completing the filing also satisfies one of the obligations in the Company's definitive acquisition agreement with Baxter International Inc. The Company expects to provide additional updates on the status of the transaction with Baxter, including the performance of certain other obligations on the part of the Company or the satisfaction or waiver of certain conditions set forth in the acquisition agreement, only after determining the results of the special shareholders' meeting to approve the acquisition. The special shareholders' meeting is expected to be held in late March.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next